Judge gives initial approval to Actavis $20m antitrust deal

A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

20 August 2019 Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.

Generics

Teva charged in DoJ antitrust probe into generic drug price-fixing

26 August 2020 Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.

Americas

Tris blocks Actavis’ ADHD generic

10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

More on this story

Americas

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

Generics

Teva charged in DoJ antitrust probe into generic drug price-fixing

26 August 2020 Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.

Americas

Tris blocks Actavis’ ADHD generic

10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

More on this story

Americas

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

Generics

Teva charged in DoJ antitrust probe into generic drug price-fixing

26 August 2020 Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.

Americas

Tris blocks Actavis’ ADHD generic

10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Judge gives initial approval to Actavis $20m antitrust deal

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features